French biotech ErVimmune raises €17M to advance its off-the-shelf cancer vaccine targeting HERVs, backed by Seventure and SPRIM Global Investments.
Amount Raised
€17 Million
Round Type
Series A
LyonBiotechnologyHealth CareInvestors
Description
ErVimmune has successfully raised €17M to further develop its innovative cancer vaccine, ErVac01, which targets 'cold' tumors. The funding was led by an international investor syndicate, including Seventure and SPRIM Global Investments. This financing will facilitate additional non-dilutive support from Bpifrance and France's 2030 investment program. The company's focus is on high medical need indications in cancer treatment.
Quick answer
ErVimmune raised €17 Million in a Series A round, dated January 21, 2026. Investors: Sprim Global Investments and Seventure. ErVimmune is based in Lyon, Auvergne Rhône Alpes, France.
- How much did ErVimmune raise?
- ErVimmune raised €17 Million in a Series A round on January 21, 2026.
- Who invested in ErVimmune?
- Sprim Global Investments and Seventure are named as investors in this round.
- What does ErVimmune do?
- ErVimmune is a Lyon-based biotech company focused on developing off-the-shelf cancer vaccines targeting human endogenous retroviruses (HERVs).
- Where is ErVimmune based and how big is it?
- ErVimmune is based in Lyon, Auvergne Rhône Alpes, France. Fundz records about 18 employees.
- Who are the decision-makers at ErVimmune?
- Fundz holds 1 contact at ErVimmune. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as ErVimmune that raised within 45 days of this round, from Fundz verified event records.
- Telo Genomics raised $7K (Pre-Seed) on March 6, 2026.
- NexCure raised $19M (Series A) on March 5, 2026.
- Raydiax raised $8.7M (Funding Round) on March 5, 2026.
- Cognito Therapeutics raised $105M (Series C) on March 5, 2026.
- Prolium Bioscience raised $50M (Series A) on March 5, 2026.
- LifeCellsNI raised $790K (Pre-Seed) on March 4, 2026.
Who to call at ErVimmune, and when
A new round usually means ErVimmune is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day ErVimmune raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at ErVimmune, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at ErVimmune. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment ErVimmune raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansErVimmune raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.